EPS for BioSpecifics Technologies Corp. (BSTC) Expected At $0.39

March 20, 2018 - By Marie Mckinney

 EPS for BioSpecifics Technologies Corp. (BSTC) Expected At $0.39
Investors sentiment decreased to 1.08 in Q3 2017. Its down 0.15, from 1.23 in 2017Q2. It fall, as 10 investors sold BioSpecifics Technologies Corp. shares while 27 reduced holdings. 16 funds opened positions while 24 raised stakes. 3.70 million shares or 3.67% less from 3.84 million shares in 2017Q2 were reported.
D E Shaw holds 5,531 shares. National Bank Of New York Mellon holds 68,324 shares or 0% of its portfolio. Cadence Cap Limited Liability Corp has invested 0.09% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Invesco Ltd reported 52,690 shares or 0% of all its holdings. Secor Cap Advsrs L P invested in 0.08% or 16,966 shares. Amer Century Companies holds 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 25,607 shares. 386,909 were reported by Blackrock. Deutsche Comml Bank Ag invested in 25,448 shares. Ativo Ltd Co holds 0.28% or 22,592 shares. Wells Fargo And Mn reported 45,108 shares. Bankshares Of America De holds 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 802 shares. Jw Asset Ltd Llc invested in 73,649 shares or 2.51% of the stock. American Intll Grp Inc reported 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Schwab Charles invested in 41,812 shares. Renaissance Technology Limited Company owns 0.02% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 415,300 shares.

Analysts expect BioSpecifics Technologies Corp. (NASDAQ:BSTC) to report $0.39 EPS on March, 21.They anticipate $0.01 EPS change or 2.50 % from last quarter’s $0.4 EPS. BSTC’s profit would be $2.80M giving it 27.38 P/E if the $0.39 EPS is correct. After having $0.37 EPS previously, BioSpecifics Technologies Corp.’s analysts see 5.41 % EPS growth. The stock increased 2.32% or $0.97 during the last trading session, reaching $42.71. About 44,711 shares traded or 60.81% up from the average. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has risen 49.91% since March 20, 2017 and is uptrending. It has outperformed by 33.21% the S&P500.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Ratings Coverage

Among 2 analysts covering BioSpecifics Technologies Corp (NASDAQ:BSTC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioSpecifics Technologies Corp has $7200 highest and $60 lowest target. $62.50’s average target is 46.34% above currents $42.71 stock price. BioSpecifics Technologies Corp had 7 analyst reports since March 8, 2016 according to SRatingsIntel. As per Wednesday, February 7, the company rating was initiated by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Buy” on Monday, November 13. As per Monday, December 11, the company rating was maintained by H.C. Wainwright. On Tuesday, December 26 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, March 13. The stock has “Buy” rating by H.C. Wainwright on Thursday, August 10. On Tuesday, March 8 the stock rating was initiated by Rodman & Renshaw with “Buy”.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has market cap of $307.05 million. The firm offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It has a 27.55 P/E ratio. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids.

More notable recent BioSpecifics Technologies Corp. (NASDAQ:BSTC) news were published by: Marketwatch.com which released: “BioSpecifics Technologies Corp.” on March 26, 2017, also Prnewswire.com with their article: “BioSpecifics Technologies Corp. Initiates Phase 1 Clinical Trial of XIAFLEX …” published on April 18, 2017, Prnewswire.com published: “BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of …” on November 17, 2016. More interesting news about BioSpecifics Technologies Corp. (NASDAQ:BSTC) were released by: Prnewswire.com and their article: “BioSpecifics Technologies Corp. Announces Partner Endo International Exercises …” published on November 05, 2015 as well as Prnewswire.com‘s news article titled: “BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2017 …” with publication date: March 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.